Skip to content

Clinical effect of modified Guipi Decoction on language function of children with cblC methylmalonic aciduria

Clinical efficacy and mechanism of Guipi Decoction in the treatment of MMA speech disorder

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004632
Enrollment
Unknown
Registered
2021-03-25
Start date
2021-03-24
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methylmalonic aciduria

Interventions

Sponsors

The First Affiliated Hospital of Henan University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 6 Years

Inclusion criteria

Inclusion criteria: (1) It was consistent with the diagnosis of cblC type MMA of deficiency of both heart and spleen; (2) For the clinical manifestations with abnormal language function, the assessment results of S-S language retardation test were referred to for the determination of language dysfunction; (3) They were aged from 1 to 5 years old; (4) The legal guardian of the child signed the informed consent and was willing to accept traditional Chinese medicine treatment and clinical investigation.

Exclusion criteria

Exclusion criteria: (1) There were severe visual impairment, hearing impairment, cardiovascular and cerebrovascular diseases; (2) Patients with other diseases that seriously affect language function, such as hypothyroidism and hydrocephalus; (3) Patients with severe infection, abnormal liver and kidney function and metabolic disorder.

Design outcomes

Primary

MeasureTime frame
S-S language retardation test;

Secondary

MeasureTime frame
Pedsqltm 4.0 universal core scale;

Countries

China

Contacts

Public ContactZhang Fan

The First Affiliated Hospital of Henan University of traditional Chinese Medicine

zhangfan777777@126.com+86 15890180506

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026